Key Highlights • Zydus launched Semaglutide under SEMAGLYN™, MASHEMA™, ALTERME™️ • Monthly cost around ₹2,200, improving affordability • Features reusable multi-dose pen for better convenience and adherence • Approved by DCGI for Type 2 Diabetes & Obesity treatment • Sun Pharma launched Noveltreat (weight loss) and Sematrinity (diabetes) • Pricing ranges ₹750–2,000 per week, significantly cheaper than innovator drugs • Offers multiple dose strengths with user-friendly pre-filled pens Why It Matters Affordable Semaglutide launches can expand access to diabetes and obesity treatment in India, unlocking a large addressable market and intensifying competition in the GLP-1 segment. Learning Outcome When patents expire, generic launches can disrupt pricing and increase adoption. Investors should track pricing strategy, market share gains, and scalability in high-growth therapy areas.

ZYDUSLIFE

SPARC

#StockInNews#FundamentalViews

427 likes·77 comments